Corporate Responsibility
Corporate Responsibility

Patient Assistance Program (PAP)

The Takeda Patient Assistance Program (PAP) provides patients with access to medications for a variety of conditions.

CAN I APPLY?

  • 1. You are a legal resident of the United States. You must live in the United States and for some assistance programs must provide proof of residency with either a Social Security Number, Green Card Number or Visa Number.
  • 2. You do not have prescription coverage through private or government programs.
  • 3. If you are eligible for, or enrolled in, Medicare Part D, you may still apply – see Sections 4 and 5 of the application form for guidelines.
    • a. Attach a copy of the Social Security Low Income Subsidy (LIS) denial letter, if applicable.
    • b. Applicants will be referred when income is less than 135% of  Federal Poverty Level (FPL) guidelines.
    • c. For further information, applicants can refer to www.socialsecurity.gov or may call 1-800-772-1213 (TTY 1-800-325-0778).
  • 4. Your total household incomeYour yearly household income includes all money that comes into your household. If you are married and live with your spouse, you must include both of your incomes. You must also include income earned by dependents living with you. does not exceed:

Persons in Household Annual Income
1 $32,670
2 $44,130
3 $55,590
4 $67,050
5 $78,510

Takeda Medicines Available through the Patient Assistance Program


MEDICATION (generic)
These are the products Takeda has available to patients in the PAP:
ACTOS (pioglitazone HCl) Duetact (pioglitazone HCl and glimepiride)
ACTOplus met (pioglitazone HCl + metformin HCl) EDARBI (azilsartan medoxomil)
ACTOplus met XR (pioglitazone HCl + metformin HCl XR) Rozerem (ramelteon)
AMITIZA (lubiprostone) ULORIC (febuxostat)
DEXILANT (dexlansoprazole)

ACTOS, ACTOplus met, ACTOplus met XR, duetact, EDARBI and Rozerem are trademarks of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

AMITIZA is a trademark of Sucampo Pharmaceuticals, Inc. registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

DEXILANT is a trademark of Takeda Pharmaceuticals North America, Inc., registered in the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

ULORIC is a trademark of Teijin Pharma Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.

This program, as well as all Takeda Pharmaceuticals America, Inc. programs, can be discontinued or changed at any time without notice at the discretion of Takeda Pharmaceuticals America, Inc.

Patient Assistance Program

In 2010, the Takeda Patient Assistance Program provided more than 78,000 patients with 186,000 prescriptions valued at $104 million.

On October 31, 2011, the Takeda Patient Assistance Program changed pharmacy providers.

To avoid delays in processing new patient applications, download a new application now!

The new address is:
Takeda Patient Assistance Program
P.O. Box 5727
Louisville, KY 40255-0727

Phone and fax numbers remain the same:
1.800.830.9159
1.800.497.0928 fax





Page Top